FDA clearance is a critical regulatory milestone that can significantly impact a biotech company's stock price. It not only validates the company's research and development efforts but also enhances its credibility in the industry. This approval likely increases investor confidence in BioRestorative Therapies, potentially leading to a positive short-term impact on its stock price. The advancement of BRTX-100 into later stages of clinical trials could also attract more attention from investors and partners interested in its therapeutic potential.